SC9 Incorporates 21 Patented Features Designed to Position the Lens for Superior Intermediate Vision
Model SC9 Intraocular Lens. (Credit: PR Newswire/ CORD, LLC)
CORD, LLC, a privately held ophthalmic medical device company, announced today that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Model SC9 Intraocular Lens (IOL) for the treatment of cataracts.
The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has been at the forefront of technology to improve and enhance vision for more than four decades. He is a pioneer in IOL research and development, with over one hundred patents related to intraocular lenses. Dr. Cumming designed the Crystalens®, approved by the FDA in 2003.
The SC9 lens was designed to treat cataract patients with a single focus spherical optic and a rigid structure to consistently locate the optic in a position intended to provide intermediate vision that is superior to that of a standard monofocal IOL.
CORD is seeking market approval of the SC9 intraocular lens based on the results of more than 300 patients who were followed for a minimum of one year under an approved Investigational Device Exemption (IDE).
Source: Company Press Release